???global.info.a_carregar???
Bruno Costa (BC) is a Principal Investigator contracted by the School of Medicine, University of Minho (Portugal), working at the Life and Health Sciences Research Institute (ICVS). He graduated in Applied Biology in 2003 and completed his PhD degree in Health Sciences in December 2008 by the University of Minho. During his PhD studies, BC also worked for 2 years at the UCSF (University of California, San Francisco, USA) under the supervision of Prof. Joseph Costello. Between January 2009 and June 2013, he was a Post-Doc fellow from FCT (Portugal) at the ICVS/3B's, a Portuguese Associate Laboratory. During his scientific career, BC has also worked in other research groups in Portugal (University of Porto and University of Minho), and in the Netherlands (Leiden University Medical Centre). More recently, BC was granted various highly competitive positions, including an FCT Investigator position (starting grant) in 2013, a CEEC Assistant Researcher position in 2019, and secured a permanent position as an Assistant Researcher at the University of Minho in December 2021. BC is mainly interested in the study of molecular (genetic and epigenetic) and cellular hallmarks of human brain tumors, and how these can be translated into therapeutic and prognostic values, contributing to a precision medicine approach in brain cancer care. Of all brain tumors, glioblastoma (GBM) is particularly devastating, being the most common and most malignant type. The clinical outcomes are very poor and vary greatly among patients. Paradoxically, GBM patients are almost always treated with a "one fits all" standard approach, mostly because good prognostic and therapy response biomarkers are still lacking. Using a wide panoply of biological samples, ranging from preclinical in vitro and in vivo models, to primary tumor and biofluid samples obtained from patients, BC has been focused on better defining the heterogeneous molecular and cellular landscapes of GBM, identifying novel clinically-useful biomarkers, and exploiting novel therapeutic strategies to target key oncogenic features. BC has accumulated 22 honors/prizes, including prestigious recognitions from the Calouste Gulbenkian Foundation (2010 Award on Cutting Edge Research in Life Sciences), the Luso-American Development Foundation, and the Portuguese League Against Cancer. He directly secured ~745.000 ¿ as projects PI/co-PI from various funding agencies, plus 250.000¿ as a team member of institutional projects, and 492.500¿ as FCT salary grants. He was an invited speaker in 29 communications, including 8 plenary talks, and was a guest editor for 4 international scientific journals. His work as project leader was awarded with 12 best poster/oral communication prizes in scientific meetings. BC has been an invited grant evaluator for 6 international funding agencies, and a recurring referee for >30 ISI-index international journals. BC successfully supervised 8 PhD, 10 MSc, and 6 Medical (final-year project) students who already concluded their thesis, and is currently the supervisor of 2 Post-Docs, 3 PhD and 1 MSc students. He has been a main organizer of multiple annual editions of 6 post-graduation courses at the School of Medicine, 1 international EMBO workshop (2014), and a jury member in 12 MSc and 7 PhD defenses (excluding those at University of Minho). BC was an elected member of the School Council of the School of Medicine (2015-2020), and a Board Member of the Portuguese Association for Cancer Research (2020-2024), and a National Delegate MC Member of 2 European COST Actions (CA18206 granted in 2019, and CA22103 granted in 2023) in the field of Neuro-Oncology. He was recently listed in the "World¿s Top 2% Scientists 2023¿ according to a study by the University of Stanford and the publishing company Elsevier. Bruno Costa's PubMed "My Bibliography" (H-index = 25) can be found here: https://www.ncbi.nlm.nih.gov/myncbi/1hiYjn7r551QA/bibliography/public/
Ler resumo completo ↓
Identificação

Identificação pessoal

Nome completo
Bruno Costa

Identificadores de autor

Ciência ID
9F15-B5B0-65B2
ORCID iD
0000-0003-4861-7432
Google Scholar ID
9CexSGEAAAAJ&
Researcher Id
U-1694-2017
Scopus Author Id
57050722300

Websites

Domínios de atuação

  • Ciências Médicas e da Saúde - Medicina Básica
  • Ciências Médicas e da Saúde - Ciências da Saúde
  • Ciências Médicas e da Saúde - Outras Ciências Médicas - Outras Áreas das Ciências Médicas
  • Ciências Médicas e da Saúde - Biotecnologia Médica - Diagnóstico e Terapias de Base Genética

Idiomas

Idioma Conversação Leitura Escrita Compreensão Peer-review
Inglês Utilizador proficiente (C2) Utilizador proficiente (C2) Utilizador proficiente (C2) Utilizador proficiente (C2) Utilizador proficiente (C2)
Português Utilizador proficiente (C2) Utilizador proficiente (C2) Utilizador proficiente (C2) Utilizador proficiente (C2) Utilizador proficiente (C2)
Espanhol; Castelhano Utilizador independente (B1) Utilizador independente (B1) Utilizador elementar (A1) Utilizador independente (B1)
Francês Utilizador elementar (A1) Utilizador independente (B1) Utilizador elementar (A1) Utilizador independente (B1)
Italiano Utilizador elementar (A1) Utilizador elementar (A1) Utilizador elementar (A1) Utilizador elementar (A1)
Formação
Grau Classificação
2009/01/01 - 2013/06/30
Concluído
 Epigenetic Transcriptional Regulators and Downstream Targets of HOXA9: Functional and Clinical Implications for Human Glioma (Pós-doutoramento)
Universidade do Minho, Portugal
2009 - 2009
Concluído
 Laboratory Animal Science (LAS) according to the European Regulations (Federation of Laboratory Animal Science Associations, FELASA) (Outros)
Universidade do Minho, Portugal
2008/12/05
Concluído
 Molecular Determinants of Glioma Risk and Patient Prognosis (Doutoramento)
Universidade do Minho Escola de Medicina, Portugal
"Molecular Determinants of Glioma Risk and Patient Prognosis" (TESE/DISSERTAÇÃO)
 Aprovado por unanimidade
2003/07/31
Concluído
 Biologia Aplicada (Licenciatura)
Universidade do Minho Escola de Ciências, Portugal
"The role of PRMT5 and associated proteins in transcription and cell cycle control" (TESE/DISSERTAÇÃO)
 16
Percurso profissional

Ciência

Categoria Profissional
Instituição de acolhimento 		Empregador
2018/07/05 - 2020/03/31 Investigador Auxiliar (carreira) (Investigação) Universidade do Minho Instituto de Investigação em Ciências da Vida e Saúde, Portugal
2013/07/01 - 2018/06/30 Investigador Auxiliar (carreira) (Investigação) Laboratório Associado ICVS 3B's, Portugal
2009/01/01 - 2013/06/30 Pós-doutorado (Investigação) Laboratório Associado ICVS 3B's, Portugal
2005/01/01 - 2008/12/31 Investigador (Investigação) Universidade do Minho, Portugal
2006/05/01 - 2007/12/31 Investigador visitante (Investigação) University of California San Francisco, Estados Unidos
University of California San Francisco Brain Tumor Research Center, Estados Unidos
2004/01/01 - 2004/10/31 Investigador (Investigação) Universidade do Porto, Portugal
Universidade do Porto Instituto de Biologia Molecular e Celular, Portugal
(...)
2003/03/01 - 2003/07/31 Estagiário de Investigação (Investigação) Leids Universitair Medisch Centrum, Países Baixos

Docência no Ensino Superior

Categoria Profissional
Instituição de acolhimento 		Empregador
2016 - Atual Leitor (Docente Universitário) Universidade do Minho Escola de Medicina, Portugal

Outros

Categoria Profissional
Instituição de acolhimento 		Empregador
2015/01/20 - 2020/03/31 Member of the School Council at the School of Medicine, University of Minho, Portugal Universidade do Minho Escola de Medicina, Portugal
Projetos

Bolsa

Designação Financiadores
2014/01 - 2015/12 Surface-Engineered Dendrimers as Novel Nanocarriers for the Delivery of Temozolomide Chemotherapy into Malignant Brain Tumors
Nanocarriers for Brain Tumors
Investigador responsável
Laboratório Associado ICVS 3B's, Portugal
 Laboratório Associado ICVS 3B's
Concluído
2011/04/01 - 2014/09/30 The Transcriptome of the Oncogenic HOXA9 Homeoprotein in Human Glioblastoma: Characterization and Functional Significance
Provided by PTCRIS: 113795
PTDC/SAU-GMG/113795/2009
Investigador responsável
Fundação para a Ciência e a Tecnologia
Concluído
2010 - 2012 The Transcriptome of the Oncogenic HOXA9 Homeoprotein in Glioblastoma and Precursor Cells
Programa de Investigação na Fronteira das Ciências da Vida
Investigador responsável
Fundação Calouste Gulbenkian, Portugal
Concluído
2010 - 2012 Implicação da Expressão do Biomarcador Oncogénico HOXA9 na Resposta de Células de Glioblastoma Humano a Agentes Terapêuticos
Bolsa Liga Portuguesa Contra o Cancro
Investigador responsável
Concluído
Produções

Publicações

Artigo em revista
  1. Mendanha, D.; Gimondi, S.; Costa, B.M.; Ferreira, H.; Neves, N.M.. "Microfluidic-derived docosahexaenoic acid liposomes for glioblastoma therapy". Nanomedicine: Nanotechnology, Biology and Medicine 53 (2023): 102704. http://dx.doi.org/10.1016/j.nano.2023.102704.
    10.1016/j.nano.2023.102704
  2. OUTEIRO-PINHO, GONÇALO; BARROS-SILVA, DANIELA; MOREIRA-SILVA, FILIPA; LOBO, JOÃO; CARNEIRO, ISA; MORAIS, ANTÓNIO; MARTINS, EDUARDA P.; et al. "Epigenetically-regulated miR-30a/c-5p directly target TWF1 and hamper ccRCC cell aggressiveness". Translational Research 249 (2022): 110-127. http://dx.doi.org/10.1016/j.trsl.2022.06.009.
    10.1016/j.trsl.2022.06.009
  3. Lopes M; de Castro, J. Vieira; Pojo M; Gonçalves CS; Martins EP; Coimbra B; Sotiropoulos, Ioannis; et al. Autor correspondente: Costa, Bruno M.. "Chronic stress does not influence the survival of mouse models of glioblastoma". Frontiers in Oncology (2022):
    Aceite para publicação
  4. Pacheco, Catarina; Martins, Cláudia; Monteiro, Joaquim; Baltazar, Fátima; Costa, Bruno M.; Sarmento, Bruno. "Glioblastoma Vasculature: From its Critical Role in Tumor Survival to Relevant in Vitro Modelling". Frontiers in Drug Delivery 2 (2022): http://dx.doi.org/10.3389/fddev.2022.823412.
    10.3389/fddev.2022.823412
  5. Clement, Patricia; Smits, Marion; van Osch, Matthias J. P.; Costa, Bruno M.; Warnert, Esther A. H.. "Micro- to macroscale magnetic resonance imaging of glioma". Magnetic Resonance Materials in Physics, Biology and Medicine (2022): http://dx.doi.org/10.1007/s10334-021-00999-w.
    10.1007/s10334-021-00999-w
  6. Martins-Lima, Cláudia; Miranda-Gonçalves, Vera; Lobo, João; Constâncio, Vera; Leite-Silva, Pedro; Guimarães-Teixeira, Catarina; Monteiro-Reis, Sara; et al. "Cadherin switches during epithelial-mesenchymal transition: CDH4/RCAD downregulation reduces bladder cancer progression". Cellular Oncology (2022): http://dx.doi.org/10.1007/s13402-021-00657-2.
    10.1007/s13402-021-00657-2
  7. Martins, Eduarda P.; Gonçalves, Céline S.; Pojo, Marta; Carvalho, Rita; Ribeiro, Ana S.; Miranda-Gonçalves, Vera; Taipa, Ricardo; et al. Autor correspondente: Costa, Bruno M.. "Cadherin-3 is a novel oncogenic biomarker with prognostic value in glioblastoma". Molecular Oncology (2021): http://dx.doi.org/10.1002/1878-0261.13162.
    10.1002/1878-0261.13162
  8. Pacheco, Catarina; Baltazar, Fátima; Costa, Bruno M.; Sarmento, Bruno. "Bringing vascularization into glioblastoma in vitro models". Trends in Molecular Medicine (2021): http://dx.doi.org/10.1016/j.molmed.2021.11.001.
    10.1016/j.molmed.2021.11.001
  9. Celus, Ward; Oliveira, Ana I.; Rivis, Silvia; Van Acker, Heleen H.; Landeloos, Ewout; Serneels, Jens; Cafarello, Sarah Trusso; et al. "PlexinA4 mediates cytotoxic T cell trafficking and exclusion in cancer". Cancer Immunology Research (2021): canimm.CIR-21. http://dx.doi.org/10.1158/2326-6066.cir-21-0061.
    10.1158/2326-6066.cir-21-0061
  10. Miranda-Gonçalves, Vera; Gonçalves, Céline S.; Granja, Sara; Vieira de Castro, Joana; Reis, Rui M.; Costa, Bruno M.; Baltazar, Fátima. "MCT1 Is a New Prognostic Biomarker and Its Therapeutic Inhibition Boosts Response to Temozolomide in Human Glioblastoma". Cancers 13 14 (2021): 3468. http://dx.doi.org/10.3390/cancers13143468.
    Acesso aberto • 10.3390/cancers13143468
  11. Daniel Mendanha; Joana Vieira de Castro; Joana Moreira; Bruno M. Costa; Honorina Cidade; Madalena Pinto; Helena Ferreira; Nuno M. Neves. "A New Chalcone Derivative with Promising Antiproliferative and Anti-Invasion Activities in Glioblastoma Cells". Molecules 26 11 (2021): 3383-3383. https://doi.org/10.3390/molecules26113383.
    10.3390/molecules26113383
  12. Oliveira, Catarina; Gonçalves, Céline S.; Martins, Eduarda P.; Neves, Nuno M.; Reis, Rui L.; Costa, Bruno M.; Silva, Tiago H.; Martins, Albino. "Fucoidan/chitosan nanoparticles functionalized with anti-ErbB-2 target breast cancer cells and impair tumor growth in vivo". International Journal of Pharmaceutics 600 (2021): 120548. http://dx.doi.org/10.1016/j.ijpharm.2021.120548.
    Publicado • 10.1016/j.ijpharm.2021.120548
  13. H, Marcelino; TMA, Carvalho; J, Tomás; FI, Teles; AC, Honório; CB, Rosa; AR, Costa; et al. "Adenosine inhibits cell proliferation differently in human astrocytes and in glioblastoma cell lines". Neuroscience (2021): http://dx.doi.org/10.1016/j.neuroscience.2021.05.019.
    10.1016/j.neuroscience.2021.05.019
  14. Le Boiteux, Elisa; Court, Franck; Guichet, Pierre-Olivier; Vaurs-Barrière, Catherine; Vaillant, Isabelle; Chautard, Emmanuel; Verrelle, Pierre; et al. "Widespread overexpression from the four DNA hypermethylated HOX clusters in aggressive (IDHwt) glioma is associated with H3K27me3 depletion and alternative promoter usage". Molecular Oncology (2021): http://dx.doi.org/10.1002/1878-0261.12944.
    Publicado • 10.1002/1878-0261.12944
  15. Lopes, Marta B.; Martins, Eduarda P.; Vinga, Susana; Costa, Bruno M.. "The Role of Network Science in Glioblastoma". Cancers 13 5 (2021): 1045. http://dx.doi.org/10.3390/cancers13051045.
    Acesso aberto • Publicado • 10.3390/cancers13051045
  16. Vieira de Castro, Joana; S. Gonçalves, Céline; P. Martins, Eduarda; Miranda-Lorenzo, Irene; T. Cerqueira, Mariana; Longatto-Filho, Adhemar; A. Pinto, Afonso; et al. Autor correspondente: M. Costa, Bruno. "Intracellular Autofluorescence as a New Biomarker for Cancer Stem Cells in Glioblastoma". Cancers 13 4 (2021): 828. http://dx.doi.org/10.3390/cancers13040828.
    10.3390/cancers13040828
  17. Paulo Linhares; Bruno Carvalho; Rui Vaz; Bruno M. Costa. "Glioblastoma: Is There Any Blood Biomarker with True Clinical Relevance?". International Journal of Molecular Sciences 21 16 (2020): 5809-5809. https://doi.org/10.3390/ijms21165809.
    10.3390/ijms21165809
  18. Joana Vieira de Castro; Céline S. Gonçalves; Adília Hormigo; Bruno M. Costa. Autor correspondente: Bruno M. Costa. "Exploiting the Complexities of Glioblastoma Stem Cells: Insights for Cancer Initiation and Therapeutic Targeting". International Journal of Molecular Sciences (2020): https://doi.org/10.3390/ijms21155278.
    10.3390/ijms21155278
  19. Oliveira-Pinto, Sofia; Pontes, Olívia; Lopes, Diogo; Sampaio-Marques, Belém; Costa, Marta D.; Carvalho, Luísa; Gonçalves, Céline S.; et al. "Unravelling the anticancer potential of functionalized chromeno[2,3-b]pyridines for breast cancer treatment". Bioorganic Chemistry 100 (2020): 103942. http://dx.doi.org/10.1016/j.bioorg.2020.103942.
    10.1016/j.bioorg.2020.103942
  20. Outeiro-Pinho, Gonçalo; Barros-Silva, Daniela; Aznar, Elena; Sousa, Ana-Isabel; Vieira-Coimbra, Márcia; Oliveira, Jorge; Gonçalves, Céline S.; et al. "MicroRNA-30a-5pme: a novel diagnostic and prognostic biomarker for clear cell renal cell carcinoma in tissue and urine samples". Journal of Experimental & Clinical Cancer Research 39 1 (2020): http://dx.doi.org/10.1186/s13046-020-01600-3.
    10.1186/s13046-020-01600-3
  21. Gonçalves, Céline S.; Le Boiteux, Elisa; Arnaud, Philippe; Costa, Bruno M.. Autor correspondente: Costa, Bruno M.. "HOX gene cluster (de)regulation in brain: from neurodevelopment to malignant glial tumours". Cellular and Molecular Life Sciences (2020): http://dx.doi.org/10.1007/s00018-020-03508-9.
    Publicado • 10.1007/s00018-020-03508-9
  22. Gonçalves, Céline S.; Xavier-Magalhães, Ana; Martins, Eduarda P.; Pinto, Afonso A.; Pires, Manuel Melo; Pinheiro, Célia; Reis, Rui M.; Sousa, Nuno; Costa, Bruno M.. Autor correspondente: Costa, Bruno M.. "A novel molecular link between HOXA9 and WNT6 in glioblastoma identifies a subgroup of patients with particular poor prognosis". Molecular Oncology (2020): http://dx.doi.org/10.1002/1878-0261.12633.
    10.1002/1878-0261.12633
  23. Estevão-Pereira, Helena; Lobo, João; Salta, Sofia; Amorim, Maria; Lopes, Paula; Cantante, Mariana; Reis, Berta; et al. "Overexpression of circulating MiR-30b-5p identifies advanced breast cancer". Journal of Translational Medicine 17 1 (2019): http://dx.doi.org/10.1186/s12967-019-02193-y.
    10.1186/s12967-019-02193-y
  24. Branco, Mariana; Linhares, Paulo; Carvalho, Bruno; Santos, Patrícia; Costa, Bruno M.; Vaz, Rui. "Serum lactate levels are associated with glioma malignancy grade". Clinical Neurology and Neurosurgery 186 (2019): 105546. http://dx.doi.org/10.1016/j.clineuro.2019.105546.
    10.1016/j.clineuro.2019.105546
  25. Brown, Peter; Tan, Aik-Choon; El-Esawi, Mohamed A; Liehr, Thomas; Blanck, Oliver; Gladue, Douglas P; Almeida, Gabriel M F; et al. "Large expert-curated database for benchmarking document similarity detection in biomedical literature search". Database 2019 (2019): http://dx.doi.org/10.1093/database/baz085.
    10.1093/database/baz085
  26. Salgado AJ; Gimble JM; Costa BM. "The cell secretome in personalized and regenerative medicine.". Biochimie (2018): http://europepmc.org/abstract/med/30419261.
    10.1016/j.biochi.2018.11.004
  27. Mancini, Andrew; Xavier-Magalhães, Ana; Woods, Wendy S.; Nguyen, Kien-Thiet; Amen, Alexandra M.; Hayes, Josie L.; Fellmann, Christof; et al. "Disruption of the ß1L Isoform of GABP Reverses Glioblastoma Replicative Immortality in a TERT Promoter Mutation-Dependent Manner". Cancer Cell 34 3 (2018): 513-528.e8. http://dx.doi.org/10.1016/j.ccell.2018.08.003.
    10.1016/j.ccell.2018.08.003
  28. Gomes ED; Vieira de Castro J; Costa BM; Salgado AJ. "The impact of Mesenchymal Stem Cells and their secretome as a treatment for gliomas.". Biochimie (2018): http://europepmc.org/abstract/med/30031037.
    10.1016/j.biochi.2018.07.008
  29. Ramalho-Carvalho J; Gonçalves CS; Graça I; Bidarra D; Pereira-Silva E; Salta S; Godinho MI; et al. "A multiplatform approach identifies miR-152-3p as a common epigenetically regulated onco-suppressor in prostate cancer targeting TMEM97.". Clinical epigenetics (2018): http://europepmc.org/abstract/med/29599847.
    10.1186/s13148-018-0475-2
  30. Oliveira, Ana Isabel; Xavier-Magalhães, Ana; Moreira-Barbosa, Catarina; Magalhães, Hugo; Henrique, Rui; Jerónimo, Carmen; Costa, Bruno M. Autor correspondente: Costa, Bruno M. "Influence of HOTAIR rs920778 and rs12826786 genetic variants on prostate cancer risk and progression-free survival". Biomarkers in Medicine 12 3 (2018): 257-264. http://dx.doi.org/10.2217/bmm-2017-0258.
    10.2217/bmm-2017-0258
  31. Xavier-Magalhães, Ana; Gonçalves, Céline S.; Fogli, Anne; Lourenço, Tatiana; Pojo, Marta; Pereira, Bruno; Rocha, Miguel; et al. Autor correspondente: Costa, Bruno M.. "The long non-coding RNA HOTAIR is transcriptionally activated by HOXA9 and is an independent prognostic marker in patients with malignant glioma". Oncotarget 9 21 (2018): 15740-15756. http://dx.doi.org/10.18632/oncotarget.24597.
    10.18632/oncotarget.24597
  32. Gonçalves, Céline S.; de Castro, Joana Vieira; Pojo, Marta; Martins, Eduarda P.; Queirós, Sandro; Chautard, Emmanuel; Taipa, Ricardo; et al. Autor correspondente: Costa, Bruno M.. "WNT6 is a novel oncogenic prognostic biomarker in human glioblastoma". Theranostics 8 17 (2018): 4805-4823. http://dx.doi.org/10.7150/thno.25025.
    10.7150/thno.25025
  33. Ferreira, MJ; Pires-Luís, AS; Vieira-Coimbra, Márcia; Costa-Pinheiro, Pedro; Antunes, Luís; Dias, Paula C.; Lobo, Francisco; et al. "SETDB2 and RIOX2 are differentially expressed among renal cell tumor subtypes, associating with prognosis and metastization". Epigenetics 12 12 (2017): 1057-1064. http://dx.doi.org/10.1080/15592294.2017.1385685.
    10.1080/15592294.2017.1385685
  34. Celus, Ward; Di Conza, Giusy; Oliveira, Ana Isabel; Ehling, Manuel; Costa, Bruno M.; Wenes, Mathias; Mazzone, Massimiliano. "Loss of Caveolin-1 in Metastasis-Associated Macrophages Drives Lung Metastatic Growth through Increased Angiogenesis". Cell Reports 21 10 (2017): 2842-2854. http://dx.doi.org/10.1016/j.celrep.2017.11.034.
    10.1016/j.celrep.2017.11.034
  35. Vieira de Castro, Joana; Gomes, ED; Granja, Sara; Anjo, SI; Baltazar, Fátima; Manadas, B; Salgado, AJ; Costa, BM. Autor correspondente: Costa, BM. "Impact of mesenchymal stem cells' secretome on glioblastoma pathophysiology". Journal of Translational Medicine 15 1 (2017): http://dx.doi.org/10.1186/s12967-017-1303-8.
    10.1186/s12967-017-1303-8
  36. Oliveira, Ana Isabel; Anjo, Sandra I.; Vieira de Castro, Joana; Serra, Sofia C.; Salgado, António J.; Manadas, Bruno; Costa, Bruno M.. Autor correspondente: Costa, Bruno M.. "Crosstalk between glial and glioblastoma cells triggers the "go-or-grow" phenotype of tumor cells". Cell Communication and Signaling 15 1 (2017): http://dx.doi.org/10.1186/s12964-017-0194-x.
    10.1186/s12964-017-0194-x
  37. Carvalho, Mariana R; Maia, F Raquel; Silva-Correia, Joana; Costa, Bruno M; Reis, Rui L; Oliveira, Joaquim M. "A semiautomated microfluidic platform for real-time investigation of nanoparticles’ cellular uptake and cancer cells’ tracking". Nanomedicine 12 6 (2017): 581-596. http://dx.doi.org/10.2217/nnm-2016-0344.
    10.2217/nnm-2016-0344
  38. Xavier-Magalhães, Ana; Oliveira, Ana I.; de Castro, Joana Vieira; Pojo, Marta; Gonçalves, Céline S.; Lourenço, Tatiana; Viana-Pereira, Marta; et al. Autor correspondente: Costa, Bruno M.. "Effects of the functional HOTAIR rs920778 and rs12826786 genetic variants in glioma susceptibility and patient prognosis". Journal of Neuro-Oncology 132 1 (2017): 27-34. http://dx.doi.org/10.1007/s11060-016-2345-0.
    10.1007/s11060-016-2345-0
  39. Mancini, Andrew; Xavier-Magalhaes, Ana; Woods, Wendy; Hayes, Josie; Gapinske, Michael; McKinney, Andrew; Bell, Robert; et al. "CBIO-18. HAPLOINSUFFICIENCY OF THE REGULATOR OF THE MUTANT TERT PROMOTER REVERSES GLIOBLASTOMA REPLICATIVE IMMORTALITY". Neuro-Oncology 18 suppl_6 (2016): vi39-vi39. http://dx.doi.org/10.1093/neuonc/now212.156.
    10.1093/neuonc/now212.156
  40. Miranda-Gonçalves, Vera; Granja, Sara; Martinho, Olga; Honavar, Mrinalini; Pojo, Marta; Costa, Bruno M.; Pires, Manuel M.; et al. "Hypoxia-mediated upregulation of MCT1 expression supports the glycolytic phenotype of glioblastomas". Oncotarget 7 29 (2016): http://dx.doi.org/10.18632/oncotarget.10114.
    10.18632/oncotarget.10114
  41. Almeida-Rios, Diogo; Graça, Inês; Vieira, Filipa Quintela; Ramalho-Carvalho, João; Pereira-Silva, Eva; Martins, Ana Teresa; Oliveira, Jorge; et al. "Histone methyltransferase PRMT6 plays an oncogenic role of in prostate cancer". Oncotarget 7 33 (2016): http://dx.doi.org/10.18632/oncotarget.10061.
    10.18632/oncotarget.10061
  42. Bell, R.J.A.; Rube, H.T.; Xavier-Magalhães, A.; Costa, B.M.; Mancini, A.; Song, J.S.; Costello, J.F.. "Understanding TERT promoter mutations: A common path to immortality". Molecular Cancer Research 14 4 (2016): 315-323. http://www.scopus.com/inward/record.url?eid=2-s2.0-84963856937&partnerID=MN8TOARS.
    10.1158/1541-7786.MCR-16-0003
  43. Vieira, José Pedro; Lopes, Fátima; Silva-Fernandes, Anabela; Sousa, Maria Vânia; Moura, Sofia; Sousa, Susana; Costa, Bruno M.; et al. "Variant Rett syndrome in a girl with a pericentric X-chromosome inversion leading to epigenetic changes and overexpression of the MECP2 gene". International Journal of Developmental Neuroscience 46 (2015): 82-87. http://dx.doi.org/10.1016/j.ijdevneu.2015.07.010.
    10.1016/j.ijdevneu.2015.07.010
  44. Pires-Luís, Ana Sílvia; Vieira-Coimbra, Márcia; Vieira, Filipa Quintela; Costa-Pinheiro, Pedro; Silva-Santos, Rui; Dias, Paula C; Antunes, Luís; et al. "Expression of histone methyltransferases as novel biomarkers for renal cell tumor diagnosis and prognostication". Epigenetics 10 11 (2015): 1033-1043. http://dx.doi.org/10.1080/15592294.2015.1103578.
    10.1080/15592294.2015.1103578
  45. Gonçalves, Céline S.; Xavier-Magalhães, Ana; Pojo, Marta; Oliveira, Ana Isabel; Correia, Sara; Reis, Rui M.; Sousa, Nuno; Rocha, Miguel; Costa, Bruno M.. Autor correspondente: Costa, Bruno M.. "Transcriptional profiling of HOXA9-regulated genes in human glioblastoma cell models". Genomics Data 5 (2015): 54-58. http://dx.doi.org/10.1016/j.gdata.2015.05.010.
    10.1016/j.gdata.2015.05.010
  46. Salgado, Antonio J.; Sousa, Joao C.; Costa, Bruno M.; Pires, Ana O.; Mateus-Pinheiro, António; Teixeira, F. G.; Pinto, Luisa; Sousa, Nuno. "Mesenchymal stem cells secretome as a modulator of the neurogenic niche: basic insights and therapeutic opportunities". Frontiers in Cellular Neuroscience 9 (2015): http://dx.doi.org/10.3389/fncel.2015.00249.
    10.3389/fncel.2015.00249
  47. Costa-Pinheiro, Pedro; Ramalho-Carvalho, João; Vieira, Filipa Quintela; Torres-Ferreira, Jorge; Oliveira, Jorge; Gonçalves, Céline S; Costa, Bruno M; Henrique, Rui; Jerónimo, Carmen. "MicroRNA-375 plays a dual role in prostate carcinogenesis". Clinical Epigenetics 7 1 (2015): http://dx.doi.org/10.1186/s13148-015-0076-2.
    10.1186/s13148-015-0076-2
  48. Vieira de Castro, Joana; Gonçalves, Céline S.; Costa, Sandra; Linhares, Paulo; Vaz, Rui; Nabiço, Ricardo; Amorim, Júlia; et al. Autor correspondente: Costa, Bruno M.. "Impact of TGF-ß1 -509C/T and 869T/C polymorphisms on glioma risk and patient prognosis". Tumor Biology 36 8 (2015): 6525-6532. http://dx.doi.org/10.1007/s13277-015-3343-0.
    10.1007/s13277-015-3343-0
  49. Fogli, A.; Chautard, E.; Vaurs-Barrière, C.; Pereira, B.; Müller-Barthélémy, M.; Court, F.; Biau, J.; et al. "The tumoral A genotype of the MGMT rs34180180 single-nucleotide polymorphism in aggressive gliomas is associated with shorter patients' survival". Carcinogenesis 37 2 (2015): 169-176. http://www.scopus.com/inward/record.url?eid=2-s2.0-84962033953&partnerID=MN8TOARS.
    10.1093/carcin/bgv251
  50. Pojo, M.; Gonçalves, C.S.; Xavier-Magalhães, A.; Oliveira, A.I.; Gonçalves, T.; Correia, S.; Rodrigues, A.J.; et al. Autor correspondente: Costa, B.M.. "A transcriptomic signature mediated by HOXA9 promotes human glioblastoma initiation, aggressiveness and resistance to temozolomide". Oncotarget 6 10 (2015): 7657-7674. http://www.scopus.com/inward/record.url?eid=2-s2.0-84928404326&partnerID=MN8TOARS.
    10.18632/oncotarget.3150
  51. Xavier-Magalhães, A.; Nandhabalan, M.; Jones, C.; Costa, B.M.. "Molecular prognostic factors in glioblastoma: state of the art and future challenges". CNS oncology 2 6 (2013): 495-510. http://www.scopus.com/inward/record.url?eid=2-s2.0-84925883857&partnerID=MN8TOARS.
    10.2217/cns.13.48
  52. Pojo, M.; Cerqueira, S.R.; Mota, T.; Xavier-Magalhães, A.; Ribeiro-Samy, S.; Mano, J.F.; Oliveira, J.M.; et al. "In vitro evaluation of the cytotoxicity and cellular uptake of CMCht/PAMAM dendrimer nanoparticles by glioblastoma cell models". Journal of Nanoparticle Research 15 5 (2013): http://www.scopus.com/inward/record.url?eid=2-s2.0-84875885034&partnerID=MN8TOARS.
    10.1007/s11051-013-1621-6
  53. de Mello, R.A.; Costa, B.M.; Reis, R.M.; Hespanhol, V.. "Insights into angiogenesis in non-small cell lung cancer: Molecular mechanisms, polymorphic genes, and targeted therapies". Recent Patents on Anti-Cancer Drug Discovery 7 1 (2012): 118-131. http://www.scopus.com/inward/record.url?eid=2-s2.0-83455233831&partnerID=MN8TOARS.
  54. De Mello, R.A.; Ferreira, M.; Costa, S.; Costa, B.M.; Pires, F.S.; Neves, I.; Almeida, M.I.; et al. "Association between EGF +61 genetic polymorphisms and non-small cell lung cancer increased risk in a Portuguese population: A case-control study". Tumor Biology 33 5 (2012): 1341-1348. http://www.scopus.com/inward/record.url?eid=2-s2.0-84868152951&partnerID=MN8TOARS.
    10.1007/s13277-012-0382-7
  55. Rodrigues, A.J.; Leão, P.; Pêgo, J.M.; Cardona, D.; Carvalho, M.M.; Oliveira, M.; Costa, B.M.; et al. "Mechanisms of initiation and reversal of drug-seeking behavior induced by prenatal exposure to glucocorticoids". Molecular Psychiatry 17 12 (2012): 1295-1305. http://www.scopus.com/inward/record.url?eid=2-s2.0-84870054491&partnerID=MN8TOARS.
    10.1038/mp.2011.126
  56. Costa, B.M.; Viana-Pereira, M.; Fernandes, R.; Costa, S.; Linhares, P.; Vaz, R.; Pinheiro, C.; et al. "Impact of EGFR genetic variants on glioma risk and patient outcome". Cancer Epidemiology Biomarkers and Prevention 20 12 (2011): 2610-2617. http://www.scopus.com/inward/record.url?eid=2-s2.0-83055168559&partnerID=MN8TOARS.
    10.1158/1055-9965.EPI-11-0340
  57. Araújo, A.P.; Costa, B.M.; Pinto-Correia, A.L.; Fragoso, M.; Ferreira, P.; Mário, D.-R.; Costa, S.; Reis, R.M.; Medeiros, R.. "Association between EGF +61A/G polymorphism and gastric cancer in caucasians". World Journal of Gastroenterology 17 4 (2011): 488-492. http://www.scopus.com/inward/record.url?eid=2-s2.0-79955930685&partnerID=MN8TOARS.
    10.3748/wjg.v17.i4.488
  58. Butowski, N.; Chang, S.M.; Lamborn, K.R.; Polley, M.-Y.; Pieper, R.; Costello, J.F.; Vandenberg, S.; et al. "Phase II and pharmacogenomics study of enzastaurin plus temozolomide during and following radiation therapy in patients with newly diagnosed glioblastoma multiforme and gliosarcoma". Neuro-Oncology 13 12 (2011): 1331-1338. http://www.scopus.com/inward/record.url?eid=2-s2.0-84863011588&partnerID=MN8TOARS.
    10.1093/neuonc/nor130
  59. Costa, B.M.; Caeiro, C.; Guimarães, I.; Martinho, O.; Jaraquemada, T.; Augusto, I.; Castro, L.; et al. "Prognostic value of MGMT promoter methylation in glioblastoma patients treated with temozolomide-based chemoradiation: A Portuguese multicentre study". Oncology Reports 23 6 (2010): 1655-1662. http://www.scopus.com/inward/record.url?eid=2-s2.0-77951748188&partnerID=MN8TOARS.
    10.3892/or-00000808
  60. Costa, B.M.; Smith, J.S.; Chen, Y.; Chen, J.; Phillips, H.S.; Aldape, K.D.; Zardo, G.; et al. "Reversing HOXA9 oncogene activation by PI3K inhibition: Epigenetic mechanism and prognostic significance in human glioblastoma". Cancer Research 70 2 (2010): 453-462. http://www.scopus.com/inward/record.url?eid=2-s2.0-76549121309&partnerID=MN8TOARS.
    10.1158/0008-5472.CAN-09-2189
  61. Costa, B.M.; Ferreira, P.; Costa, S.; Canedo, P.; Oliveira, P.; Silva, A.; Pardal, F.; et al. "Association between functional EGF+61 polymorphism and glioma risk". Clinical Cancer Research 13 9 (2007): 2621-2626. http://www.scopus.com/inward/record.url?eid=2-s2.0-34249104304&partnerID=MN8TOARS.
    10.1158/1078-0432.CCR-06-2606
Capítulo de livro
  1. Gonçalves, Céline S; Lourenco, Tatiana; Xavier-Magalhaes, Ana; Pojo, Marta; Costa, Bruno M. "Mechanisms of Aggressiveness in Glioblastoma: Prognostic and Potential Therapeutic Insights". In Evolution of the Molecular Biology of Brain Tumors and the Therapeutic Implications. InTech, 2013.
    10.5772/52361
  2. Pojo, Marta; Costa, Bruno M. "Molecular Hallmarks of Gliomas". In Molecular Targets of CNS Tumors. InTech, 2011.
    10.5772/21352
Edição de número de revista
  1. Clement, Patricia; Smits, Marion; van Osch, Matthias J. P.; Costa, Bruno M.; Warnert, Esther A. H.. "Micro- to macroscale magnetic resonance imaging of glioma". Magnetic Resonance Materials in Physics, Biology and Medicine (2022): http://dx.doi.org/10.1007/s10334-021-00999-w.
    Editor convidado
  2. Costa, Bruno M.; Hormigo, Adília. "Molecular and Cellular Hallmarks of Malignant Brain Tumors". International Journal of Molecular Sciences (2020): https://www.mdpi.com/journal/ijms/special_issues/mol_brain.
    Editor convidado
  3. Maunakea, A; Bernstein, AI; Costa, Bruno M.; Richardson, JR. "Epigenetic Plasticity in Brain Development and Function". Frontiers in Genetics (2019): https://www.frontiersin.org/research-topics/9017/epigenetic-plasticity-in-brain-development-and-function.
    Publicado • Co-editor
  4. Salgado, AJ; Gimble, JM; Costa, Bruno M.. "The cell secretome in personalized and regenerative medicine". Biochimie 155 (2018): https://www.sciencedirect.com/science/article/pii/S0300908418303195?via%3Dihub.
    Publicado
Livro
  1. Costa, Bruno M.; Xavier-Magalhães, A.. Molecular Determinants of Glioma Risk and Patient Prognosis. LAP LAMBERT Academic Publishing. 2012.
    Publicado
Resumo em conferência
  1. Gonçalves, C; Vieira de Castro, J; Pojo, M; Martins, EP; Taipa, R; Pinto, AA; Faria, CC; et al. "PO-473 Wnt6 expression in glioblastoma: mechanistic, functional and clinical implications". Trabalho apresentado em 25th Biennial Congress of theEuropean Association for Cancer Research (EACR), Amsterdam, 2018.
    Publicado • 10.1136/esmoopen-2018-eacr25.978
  2. Martins, EP; Pojo, M; Gonçalves, CS; Carvalho, R; Ribeiro, AS; Pardal, F; Pinto, AA; et al. "PO-105 Cdh3/p-cadherin as a novel biomarker in glioblastoma: functional and prognostic insights". Trabalho apresentado em 25th Biennial Congress of theEuropean Association for Cancer Research (EACR), Amsterdam, 2018.
    Publicado • 10.1136/esmoopen-2018-eacr25.149
  3. Oliveira, AI; Celus, W; Costa, BM; Mazzone, M. "PO-297 Plexina4 plays a role in cancer progression and immune cell infiltration". Trabalho apresentado em 25th Biennial Congress of theEuropean Association for Cancer Research (EACR), Amsterdam, 2018.
    Publicado • 10.1136/esmoopen-2018-eacr25.810
  4. Gonçalves, C.; Pojo, M.; Xavier-Magalhães, A.; de Castro, J. Vieira; Pinto, A.A.; Taipa, R.; Pardal, F.; et al. Autor correspondente: Costa, B.M.. "Regulation of WNT6 by HOXA9 in glioblastoma: functional and clinical relevance". Trabalho apresentado em 24th Biennial Congress of theEuropean Association for Cancer Research (EACR), Manchester, 2016.
    Publicado • 10.1016/s0959-8049(16)61151-6
  5. de Castro, J. Vieira; Miranda-Lorenzo, I.; Cerqueira, M.T.; Pinto, A.A.; Heeschen, C.; Costa, B.M.. Autor correspondente: Costa, B.M.. "Autofluorescence as a new biomarker to identify glioblastoma stem cells". Trabalho apresentado em 24th Biennial Congress of theEuropean Association for Cancer Research (EACR), Manchester, 2016.
    Publicado • 10.1016/s0959-8049(16)61153-x
  6. Gonçalves CS; Pojo M; Costa BM. Autor correspondente: Costa BM. "Regulation of WNT signaling by HOXA9 in glioblastoma: mechanistic, prognostic and therapeutic insights". Trabalho apresentado em SPSAS – Advances in Molecular Oncology: TranslatingMolecular Biology into Cancer Treatment, São Paulo, 2013.
  7. Vieira de Castro J; Gomes E; Silva NA; Salgado AJ; Costa BM. "Understanding how the secretome of human bone marrow-derived mesenchymal stem cells modulates glioblastoma cells". Trabalho apresentado em SPSAS – Advances in Molecular Oncology: TranslatingMolecular Biology into Cancer Treatment, São Paulo, 2013.
  8. Xavier-Magalhães A; Gonçalves CS; Lourenço T; Pojo M; Rocha M; Lopes C; Crespo I; et al. Autor correspondente: Costa BM. "Long non-coding RNA HOTAIR is transcriptionally activated by HOXA9 and is associated with poor prognosis in glioblastoma". Trabalho apresentado em SPSAS – Advances in Molecular Oncology: TranslatingMolecular Biology into Cancer Treatment, São Paulo, 2013.
  9. Magalhaes, A.; Goncalves, C.S.; Rocha, M.; Sousa, N.; Costa, B.M.. "565 HOXA9 Target Genes in Glioblastoma – Characterization and Clinical Relevance". Trabalho apresentado em 22nd Biennial Congress of the European Association for Cancer Research (EACR-22), Barcelona, 2012.
    Publicado • 10.1016/s0959-8049(12)71224-8
  10. Pojo, M.; Goncalves, T.; Fernandes, R.; Gama, B.; Sousa, N.; Costa, B.. "165 Influence of HOXA9 Expression in the Response of Glioblastoma Cells to Temozolomide". Trabalho apresentado em 22nd Biennial Congress of the European Association for Cancer Research (EACR-22), Barcelona, 2012.
    Publicado • 10.1016/s0959-8049(12)70864-x
  11. de Mello, R.A.; Ferreira, M.; Costa, B.M.; Pires, F.; Neves, I.; Duarte, N.; Figueiredo, F.; et al. "9139 POSTER Association Between +61 A/G Polymorphism in the EGF Gene and Non-Small Cell Lung Cancer Risk in Male Caucasians". Trabalho apresentado em 2011 European Multidisciplinary Cancer Congress (EMCC), Stockholm, 2011.
    Publicado • 10.1016/s0959-8049(11)72451-0
  12. Costa, B.M.; Viana-Pereira, M.; Costa, S.; Lima, J.; Soares, P.; Amorim, J.; Linhares, P.; et al. "95 Associations between functional EGFR polymorphisms and glioma risk". Trabalho apresentado em 21st Meeting of the European Association for Cancer Research, Oslo, 2010.
    Publicado • 10.1016/s1359-6349(10)70903-4
  13. Costa BM; Smith JS; Chen Y; Chen J; Philips HS; Aldape KD; Zardo G; et al. "Epigenetic activation of HOXA9 due to PI3K pathway dysfunction has functional and clinical relevance in human tumors". Trabalho apresentado em 2nd Marie Curie-Genome Architecture in Relation to Disease Meeting, Madrid, 2008.
    Publicado
  14. Costa, Bruno M.; Justin S. Smith; Chen Y; Phillips H; Aldape K; Zardo G; Nigro J; et al. "A novel prognostic subgroup of glioblastoma with activated HOX domains that are reversibly regulated through the PI3k pathway". Trabalho apresentado em 12th Annual Meeting of the Society-for-Neuro-Oncology, Texas, 2007.
    Publicado
  15. Costa BM; Smith JS; Chen Y; Aldape KD; Zardo G; Philips HS; James CD; Fridlyand J; Costello JF. "Chromosomal domains of transcriptional activation by P13K/AKT pathway alterations in glioblastomas". Trabalho apresentado em AACR Annual Meeting-- Apr 14-18, 2007, Los Angeles, 2007.
  16. Jones C; Little SE; Reis JS; Costa B; Wilkins P; Al-Sarraj S; Pearson AJ; et al. "Presence of factors predictive of response to anti-EGFR therapy in pediatric high-grade gliomas.". 2007.
  17. Costa BM; Ferreira P; Costa S; Canedo P; Oliveira P; Silva A; Pardal F; et al. "Association Between Functional EGF+61 Polymorphism and Glioma Risk". Trabalho apresentado em Marie-Curie-Genome Architecture in Relation to Disease – Conference 1: Molecular profiling of the genome, 2007.
  18. Costa B; Pinheiro C; Costa S; Fernandes R; Pereira M; Pardal F; Lopes JM; Reis RM. "No association between EGFR promoter gene polymorphisms and glioma risk.". 2006.
Tese / Dissertação
  1. Costa, Bruno M.. "Molecular Determinants of Glioma Risk and Patient Prognosis". Doutoramento, Universidade do Minho, 2008.
  2. Costa, Bruno M.. "The role of PRMT5 and associated proteins in transcription and cell cycle control". Licenciatura, Universidade do Minho, 2003.

Propriedade Intelectual

Patente
  1. Costa, BM. 2023. "WNT6 as glioblastoma oncogenic biomarker, and uses of inhibitors thereof for treating WNT6-overexpressing glioblastoma".
    Concedida/Emitida
Pedido provisório de patente
  1. 2023. "Glutaminase, Methods and Uses Thereof.".
    Divulgado
  2. 2021. "WNT6 AS GLIOBLASTOMA ONCOGENIC BIOMARKER, AND USES OF INHIBITORS THEREOF".
    Divulgado
  3. 2019. "A novel oncogene biomarker, method and uses thereof".

Outros

Outra produção
  1. Reconstruction of consensus tissue-specific metabolic models. 2018. Sara Correia; Bruno Costa; Miguel Rocha. https://doi.org/10.1101/327262.
    10.1101/327262
Atividades

Apresentação oral de trabalho

Título da apresentação Nome do evento
Anfitrião (Local do evento)
2021/11/30 New prognostic biomarkers in glioblastoma EATRIS - Success stories on biomarkers: from bench to the clinical practice. Barriers, tips and tricks.
EATRIS Spain + Portugal
2021/10/14 "Reguladores Moleculares e Celulares de Glioblastoma" XII Congresso Nacional da Associação Portuguesa de Neuro-Oncologia
Associação Portuguesa de Neuro-Oncologia
2021/05/19 Novas estratégias de combate aos tumores cerebrais. Pint Of Science Portugal
Pint Of Science Portugal
2020/09 Molecular and Cellular Hallmarks of Brain Tumors: Prognostic and Therapeutic Insights ESMRMB Annual Congress 2020
ESMRMB - The European Society for Magnetic Resonance in Medicine and Biology
2019/07/09 Key cellular and molecular regulators of malignant brain tumors PhD Advanced Course MOLECULAR BIOMARKERS AND TECHNOLOGIES
Instituto de Investigação do Medicamento, Faculdade de Farmácia, Universidade de Lisboa (Lisboa, Portugal)
2019/06/14 Key cellular and molecular regulators of malignant brain tumors Portuguese Society of Oncology - Research Course
Portuguese Society of Oncology (Coimbra, Portugal)
2019/01/11 Key cellular and molecular regulators of malignant brain tumors Seminários em Bioinformática
UTAD (Vila Real)
2018/12/06 Cellular and molecular players in malignant brain tumors Conferences in Oncobiology
2018/09/21 Key cellular and molecular regulators of malignant brain tumors SINAL 2018 - 9th Meeting on Signal Transduction
2018/01/31 Translating Mechanisms of Aggressiveness in Brain Tumors into Prognostic and Therapeutic Value XIX Jornadas Biologia Aplicada
2017/11/11 Key molecular and cellular regulators of malignant glioma: prognostic and therapeutic insights X Congresso Nacional da Associação Portuguesa de Neuro-Oncologia
Associação Portuguesa de Neuro-Oncologia
2015/12/12 Traduzindo os mecanismos de agressividade dos tumores cerebrais em valor prognóstico e terapêutico VIII Congresso Nacional da Associação Portuguesa de Neuro-Oncologia
Associação Portuguesa de Neuro-Oncologia
2015/09/15 HOXA9 as a Critical Molecular Hub in Glioma: Prognostic and Therapeutic Insights Seminars at the Clermont-Ferrand Université
(França)
2015/03/13 Cellular and molecular mechanisms of malignancy in brain tumors V Simpósio Técnico de Anatomia Patológica
2014/11 Relevância do oncogene HOXA9 em Glioblastoma: efeitos na iniciação tumoral, agressividade, e resistência à temozolamida VII Congresso Nacional de Neuro Oncologia
Associação Portuguesa de Neuro-Oncologia (Portugal)
2013/02/28 Translating Mechanisms of Aggressiveness in Brain Tumors into Prognostic and Therapeutic Value: Insights from the Oncogenic HOXA9 Homeoprotein Seminars at the Institute of Cancer Research
(Reino Unido)
2011/11/26 Central Nervous System Cells, Neoplasias, & Multiple Sclerosis Grupo de Estudo de Esclerose Múltipla
Grupo de Estudo de Esclerose Múltipla (Portugal)
2009 Relevância Funcional e Clínica do Gene HOXA9 em Glioblastoma 2nd National Congress of the Portuguese Association of Neuro-Oncology
(Portugal)
2008/05 Epigenetic activation of HOXA9 due to PI3K pathway dysfunction has functional and clinical relevance in human tumors Marie Curie - Genome Architecture in Relation to Disease, Conference 2
(Espanha)
2007/11 A novel prognostic subgroup of glioblastoma with activated HOXA domains that are reversibly regulated through the PI3K pathway 2007 Annual Meeting of the Society for Neuro-Oncology
(Estados Unidos)

Orientação

Título / Tema
Papel desempenhado 		Curso (Tipo)
Instituição / Organização
2023 - Atual Mapping the Molecular and Cellular Landscapes of Glioblastoma with Spatial Transcriptomics and Immune Signatures to Reveal Therapeutic Opportunities
Orientador
Universidade do Minho, Portugal
2023 - Atual Clinical value of a WNT6-driven Molecular Signature in Glioblastoma Liquid Biopsies
Orientador
2020/09 - Atual Multiplex detection of circulating tumor DNA using graphene electrolyte-gate field-effect transistors.
Coorientador
Universidade do Minho, Portugal
2020/09 - Atual Co-targeting of cancer glycolytic metabolism and angiogenesis through polymeric nanoparticles for glioblastoma therapeutics
Coorientador
Universidade do Porto, Portugal
2022 - 2023/12/13 Identification of Biomarkers in Gliomas via Multivariate Classification and Feature Selection Models
Coorientador
Universidade NOVA de Lisboa Faculdade de Ciências e Tecnologia, Portugal
2022 - 2023/12/05 Deciphering novel mechanisms of WNT6-driven chemotherapy resistance in human glioblastoma
Orientador
Universidade do Minho, Portugal
2018/11 - 2023/09/22 Emerging roles of the critical oncogenic molecule Cadherin-3 in glioblastoma
Orientador
Universidade do Minho Escola de Medicina, Portugal
2018/12 - 2021/11/26 Estudo de Biomarcadores em Glioblastomas: Correlação Clínica e Molecular
Coorientador
 Medicina (Doutoramento)
Universidade do Porto Faculdade de Medicina, Portugal
2018/09 - 2019/12/10 The therapeutic impact of WNT/ WNT6 inhibition and immune checkpoints blockade in Glioblastoma
Orientador
 Masters in Health Sciences (Mestrado)
Universidade do Minho Escola de Medicina, Portugal
2018/09/01 - 2019/10/16 Influence of HOXA9 in the response of glioblastoma to immune checkpoint inhibitors
Orientador
 Masters in Health Sciences (Mestrado)
Universidade do Minho Escola de Medicina, Portugal
2014 - 2019 Intercellular relationships in the tumor microenvironment: implications for cancer pathophysiology
Orientador
Universidade do Minho Escola de Medicina, Portugal
2014/09 - 2018/12 Deciphering key roles of WNT6 in glioblastoma: mechanistic, functional, and clinical insights
Orientador
2017 - 2018 CDH3/P-cadherin as a novel biomarker in gliomas: mechanistic, functional and prognostic insights
Orientador
2017 - 2018 The effects of stress and glucocorticoids in glioma aggressiveness
Orientador
2013 - 2017 Interplay between molecular and cellular players on glioma pathophysiology
Orientador
2013 - 2017 The impact of non-coding alterations in glioma: hints from HOTAIR and the TERT promoter
Orientador
2013 - 2017 Functional analysis of EXD2 in mitochondrial homeostasis
Coorientador
2015 - 2016 Long non-coding RNA HOTTIP expression and clinical impact in gliomas
Orientador
2014 - 2016 Understanding the relevance of astrocytic vesicular release in glioblastoma
Orientador
2012 - 2016 A framework for the reconstruction and analysis of tissue specific genome-scale metabolic models
Coorientador
2012 - 2016 HOXA9 as a key regulator in glioma initiation, aggressiveness and response to therapy
Orientador
2014 - 2015 Biological implications of Wnt6 expression in human glioblastoma
Orientador
2013 - 2014 Functional roles and prognostic impact of the long non-coding RNA HOTAIR in Glioblastoma
Orientador
2011 - 2013 Regulation of Wnt Signaling by HOXA9 in Glioblastoma: Mechanistic, Prognostic and Therapeutic Insights
Orientador
2011 - 2012 Influence of HOXA9 expression in the PI3K-mediated oxidative stress in GBM
Orientador
2011 - 2012 The transcriptome of the oncogenic HOXA9 homeoprotein in human glioblastoma: functional and clinical relevance
Orientador
2011 - 2012 Impact of HOXA9 expression in the response of glioblastoma to temozolomide and patient prognosis
Orientador
2010 - 2011 HOXA9-mediated mechanisms of aggressiveness in glioblastoma
Orientador

Organização de evento

Nome do evento
Tipo de evento (Tipo de participação) 		Instituição / Organização
2019/09 - Atual National Delegate of the European COST action “Glioma MR Imaging 2.0” (ID CA 18206) (2019)
2010 - Atual Member of the Organizing Committee and Teacher/Lecturer of several post-graduation courses: "Bioinformatics in Health Sciences", "Fundamentals of Genetics, Development and Neoplasia", "Fundamentals in Neuroscience", "Being a Bio-Entrepreneur" lectured annually at University of Minho (2010)
2021/11/14 - 2021/11/15 II ASPIC-ASEICA International Meeting – Current Trends in Precision Medicine in Cancer (2021/11/14 - 2021/11/15)
Encontro (Membro da Comissão Organizadora)
 ASPIC - Associação Portuguesa de Investigação em Cancro, Portugal
2019/10/18 - 2019/10/18 Invited Chair of Scientific Session "Metabolism and Cancer Progression", Annual ISCAM Meeting (2019/10/18 - 2019/10/18)
Conferência (Outra)
 International Society of Cancer Metabolism, Itália

Participação em evento

Descrição da atividade
Tipo de evento 		Nome do evento
Instituição / Organização
2022/02/28 - 2022/02/28 Invited speaker at the event "Encontros Raros: Investigadores Raros à Conversa com Doentes Raros", organized under the scope of the Rare Disease Day 2022. Rare Disease Day 2022 - "Encontros Raros: Investigadores Raros à Conversa com Doentes Raros".
2021/02/03 - 2021/02/05 Invited for "Meet the Expert" session, at the Annual Meeting of the Glioma Imaging: Bridging Clinic and Research.
Encontro
 Annual Meeting of the Glioma Imaging: Bridging Clinic and Research
2012 - 2019 Participation in annual editions of international, national and regional Science Outreach Activities: - "Portas Abertas para a Ciência"; - "Science and Technology Week"; - "Maratona da Saúde"; - "Brain Awareness Week"; - "Verão no Campus"; - "Doctor and Scientist for a Day".
Outro

Júri de grau académico

Tema
Tipo de participação 		Nome do candidato (Tipo de grau)
Instituição / Organização
2022/02/09 Treatment of triple- negative breast cancer (TNBC) through externally triggered targetless drug carriers.
Arguente
 Mónica Alexandra da Costa Cerqueira (Mestrado)
Universidade do Minho, Portugal
2021/11/24 Intercellular communication in cancer drug resistance: the role of extracellular vesicles
Arguente principal
 Ana Rita Couto Oliveira (Mestrado)
Universidade do Porto Faculdade de Medicina, Portugal
2021/06/15 Impact of the human Golgi anti-apoptotic protein (hGAAP/TMBIM4) in Glioblastoma progression. Marta Filipa Malheiro Martins (Mestrado)
Universidade de Lisboa Faculdade de Medicina, Portugal
2020/12/23 Monitoring of lung adenocarcinoma patients through the study of large chromosomal rearrangements in liquid biopsy
Arguente principal
 Sandra Catarina Vicente Coelho (Mestrado)
Instituto Politécnico do Porto Escola Superior de Saúde, Portugal
2019/11/19 Re-expression of the epigenetically silenced androgen receptor gene by DNA methyltransferase inhibitors in castration-resistant prostate cancer cell lines
Arguente principal
 Mariana Carvalho Dias Brütt Pacheco (Mestrado)
Universidade do Porto Instituto de Ciências Biomédicas Abel Salazar, Portugal
2019/11/05 Improving cancer therapy with new p53-activating agents
Arguente principal
 Rute de Fátima Azevedo Pinheiro (Mestrado)
Universidade do Porto Instituto de Ciências Biomédicas Abel Salazar, Portugal
2019/10/29 TERT Hypermethylated Oncologic Region (THOR) as a Biomarker for Breast Cancer
Arguente principal
 Joana Dias Apolónio (Doutoramento)
Universidade do Algarve, Portugal
2018 The influence of cancer cell metabolism and microenvironment on tumor progression and drug resistance
Arguente
 Diana Maria Tavares Valente (Doutoramento)
Universidade do Minho Escola de Medicina, Portugal
2018 Clinical implications of PIK3CA mutations in gliomas molecular subgroups
Arguente principal
 Cheila Martins Brito (Mestrado)
Universidade Nova de Lisboa, Portugal
2018 Cancro Hereditário e o “Cancer Previvor”
Arguente principal
 Beatriz Luciana Farias Rosadilla Monteiro (Mestrado)
Universidade do Minho Escola de Medicina, Portugal
2017 MicroRNAs deregulation in prostate cancer
Arguente
 João António Ramalho Carvalho (Doutoramento)
Universidade do Porto Instituto de Ciências Biomédicas Abel Salazar, Portugal
2017 Monocarboxylate Transporters (MCTs) in breast cancer aggressiveness: therapeutic targeting and regulatory mechanisms
Arguente
 Luísa Filipa Morais dos Santos (Doutoramento)
Universidade do Minho Escola de Medicina, Portugal
2017 MicroRNA-27a-5p Regulation by Promoter Methylation and MYC Signaling in Prostate Carcinogenesis
Arguente
 Daniela Cristina Barros Silva (Mestrado)
Universidade do Porto Instituto de Ciências Biomédicas Abel Salazar, Portugal
2017 FOLFIRI com cetuximab versus FOLFIRI com bevacizumab como tratamento em primeira linha do cancro colo-retal metastizado: um estudo retrospetivo
Arguente principal
 Cristiana Sofia Ferreira Carneiro (Mestrado)
Universidade do Minho Escola de Medicina, Portugal
2015 MicroRNA promoter methylation: potential biomarkers in prostate cancer
Arguente principal
 Jorge Silvério Torres Ferreira (Mestrado)
Universidade do Porto Instituto de Ciências Biomédicas Abel Salazar, Portugal
2014 Identification of intragenic copy number alterations and fusion genes in paediatric high grade glioma
Arguente principal
 Diana Margarida Martins Carvalho (Doutoramento)
Universidade de Coimbra Faculdade de Farmácia, Portugal
2014 Histone methylases and demethylases: the role of SMYD3 in prostate carcinogenesis
Arguente principal
 Ana Filipa Quintela Vieira (Doutoramento)
Universidade do Porto Instituto de Ciências Biomédicas Abel Salazar, Portugal
2014 Gellan Gum-Coated Gold Nanorods for Drug Delivery Applications
Arguente principal
 Sílvia Cristina Araújo Vieira (Mestrado)
Universidade do Porto Faculdade de Engenharia, Portugal
2014 Role of activated microglia in the acquisition of a stem-like phenotype in glioblastoma
Arguente principal
 Cátia Sofia Neves Neto (Mestrado)
Universidade do Porto Faculdade de Medicina, Portugal
2013 Regulation of CDH3/P-Cadherin in normal and tumour epithelial tissues
Arguente principal
 Ana Rita Lobato Cortesão Nobre (Mestrado)
Universidade do Porto Instituto de Ciências Biomédicas Abel Salazar, Portugal
2013 The role of miR-375 in prostate carcinogenesis
Arguente principal
 Pedro Filipe da Costa Pinheiro (Mestrado)
Universidade do Porto Instituto de Ciências Biomédicas Abel Salazar, Portugal

Arbitragem científica em conferência

Nome da conferência Local da conferência
2019/10/17 - 2019/10/19 Cancer Metabolic Rewiring: Mapping the Road to Clinical Translation International Society of Cancer Metabolism
2014/10/22 - 2014/10/25 Epigenetic plasticity: Implications in neural (dys)function EMBO

Comissão de avaliação

Descrição da atividade
Tipo de assessoria 		Instituição / Organização Entidade financiadora
2020/10 - Atual Invited grant evaluator for “National Science Centre", Poland
Avaliador
2020/02 - Atual Evalutor of 3 project applications for the 2CA - Clinical Academic Center (Braga, Portugal)
Avaliador
2019 - Atual Invited grant evaluator for “ERA-NET” (a European Commission programme)
Avaliador
 European Commission
2018 - Atual Invited grant evaluator for “World Cancer Research”
Avaliador
 World Cancer Research Fund
2018 - Atual Invited grant evaluator for “INSERM” (France)
Avaliador
 INSERM
2018 - Atual Invited grant evaluator for “The Cancer Society of New Zealand”
Avaliador
 The Cancer Society of New Zealand
2016 - Atual Invited grant evaluator for “Fondation contre le Cancer” (Belgium)
Avaliador
 Fondation contre le Cancer
2010 - 2019 Invited Reviewer for 26 ISI-indexed international scientific journals
Avaliador

Consultoria / Parecer

Descrição da atividade Instituição / Organização
2021/12 - Atual Consulting activities for industrial partner (Sea4Us, PT) on preclinical validation of therapies for breast cancer.
2020 - 2021 Consulting activities for industrial partner (Targtex, PT) on preclinical validation of therapies for glioblastoma.
2014 - 2017 Consulting activities for industrial partner (Biotecnol, UK) on preclinical validation of immunotherapies for mesothelioma.

Entrevista / Programa (rádio / tv)

Programa Tema
2010/01/21 - 2010/01/21 Portugal em Direto

Membro de associação

Nome da associação Tipo de participação
2020 - Atual Portuguese Association for Cancer Research (ASPIC) Directive Board Member
2020 - Atual European COST Action (CA18206: GliMR 2.0) National Delegate MC Member
2010 - Atual European Association for Cancer Research (EACR) Active Member

Membro de comissão

Descrição da atividade
Tipo de participação 		Instituição / Organização
2021/11/14 - Atual Scientific Chair of "Target-based Cancer Therapies" Thematic Session, at the II ASPIC-ASEICA International Meeting – Current Trends in Precision Medicine in Cancer ASPIC - Associação Portuguesa de Investigação em Cancro, Portugal
2020 - Atual PhD Thesis Committee member for Carolina Noronha (Faculdade de Medicina, Universidade do Porto, Portugal) Universidade do Porto, Portugal
2020 - Atual PhD Thesis Committee member for Carlos Custódia (Instituto de Medicina Molecular, Faculdade de Medicina da Universidade de Lisboa , Portugal) Universidade de Lisboa Faculdade de Medicina, Portugal
2019/09 - Atual PhD Thesis Committee member for Cláudia Martins (ICBAS, Instituto de Ciências Biomédicas Abel Salazar, Universidade do Porto, Portugal)
Consultor
 Universidade do Porto Instituto de Ciências Biomédicas Abel Salazar, Portugal
2018 - Atual MSc Thesis Committee member for Isabella Gomes (Hospital de Câncer de Barretos, Brazil)
Consultor
 Hospital de Amor, Brasil
2017 - Atual PhD Thesis Committee member for Nadiya Kubasova (Universidade Nova de Lisboa, Portugal)
Consultor
 Universidade Nova de Lisboa Centro de Estudos de Doenças Crónicas, Portugal
2017 - Atual PhD Thesis Committee member for Elisa Le Boiteux (Clermont-Ferrand, France)
Consultor
 Université Clermont Auvergne, França
2021 - 2025 PhD Thesis Committee member for Ana Sofia Sousa Ferraz (PhD in Applied Psychology)
Consultor
 Universidade do Minho, Portugal

Tutoria

Tópico Nome do aluno
2021/04/30 - Atual Targeting the CCL2/CCR2 axis in metastatic medulloblastoma Carlos Custódia
2021 - Atual Contribuição dos Fatores Psicológicos Familiares para a Qualidade de Vida em Crianças com Leucemia Linfoblástica Aguda e Bem-Estar Familiar: Um Estudo Longitudinal Ana Sofia Sousa Ferraz
2020/03 - Atual CROSSTALK BETWEEN THE IMMUNE SYSTEM AND STEM CELLS: ROLE IN GLIOMAGENESIS Carolina Noronha
2019/09 - Atual Multi-targeted docetaxel polymeric nanoparticles as delivery systems for chemotherapy to treat glioblastoma Cláudia Martins (PhD Student, ICBAS, U. Porto, Portugal)
2016 - 2022 Epigenetics and Genetics of Hematopoietic Stem Cells Heterogeneity Nadiya Kubasova
2018 - 2020 IDENTIFICAÇÃO DE BIOMARCADORES PREDITIVOS DA SOBREVIDA AO TRATAMENTO COM TEMOZOLOMIDA NO GLIOBLASTOMA Isabella Gomes
2017 - 2018 HOX genes deregulation in Glioma Elisa Le Boiteux
Distinções

Prémio

2024 Best Oral presentation at the XIV Congress of the Portuguese Association of Neuro-Oncology
Associação Portuguesa de Neuro-Oncologia, Portugal
2023 Best Poster Presentation at the ASPIC-ASEICA International Meeting
European Association For Cancer Research, Reino Unido
2019 Best Oral presentation at the XI Congress of the Portuguese Association of Neuro-Oncology
Associação Portuguesa de Neuro-Oncologia, Portugal
2019 Best Paper Award (Paper with highest impact factor from ICVS in 2018)
Universidade do Minho Instituto de Investigação em Ciências da Vida e Saúde, Portugal
2018 Best Poster Award at the ICVS Open Day - 2018
Laboratório Associado ICVS 3B's, Portugal
2018 Best Poster Award at the 3rd ASPIC (Portuguese Association of Cancer Research) Congress
European Association For Cancer Research, Reino Unido
2017 Best Oral presentation at the X Congress of the Portuguese Association of Neuro-Oncology
Associação Portuguesa de Neuro-Oncologia, Portugal
2017 Best Poster Award at the ICVS Open Day - 2017
Laboratório Associado ICVS 3B's, Portugal
2016 Best Oral presentation at the 2nd ASPIC International Congress
ASPIC - Associação Portuguesa de Investigação em Cancro, Portugal
2014 Best Oral presentation at the VIII Congress of the Portuguese Association of Neuro-Oncology
Associação Portuguesa de Neuro-Oncologia, Portugal
2013 Best Poster Award at the XXII Porto Cancer Meeting
Roche, Hungria
2013 Best Poster Award at the VI Congress of the Portuguese Association of Neuro-Oncology
Associação Portuguesa de Neuro-Oncologia, Portugal
2010 Programa de Investigação na Fronteira das Ciências da Vida 2010 (50.000 EUR)
Fundação Calouste Gulbenkian, Portugal
2003 Best Student of Applied Biology in 1999 to 2003
Universidade do Minho, Portugal
2002 Merit Diploma 2001/2002
Universidade do Minho, Portugal
2001 Merit Diploma 2000/2001
Universidade do Minho, Portugal
2000 Merit Diploma 1999/2000
Universidade do Minho, Portugal

Título

2015 Member of the Council of the School (School of Medicine, University of Minho)

Outra distinção

2020 Direction / Board Member of the Portuguese Association for Cancer Research (ASPIC)
ASPIC - Associação Portuguesa de Investigação em Cancro, Portugal
2020 National Delegate MC Member of a European COST Action (CA18206).
European Cooperation in Science and Technology, Bélgica
2019 CEEC Assistant Researcher position
Fundação para a Ciência e a Tecnologia, Portugal
2014 EMBO sponsorship for Organization of an International Workshop
EMBO Press, Alemanha
2013 Meeting Bursary Award
European Association For Cancer Research, Reino Unido
2013 Investigator FCT
Fundação para a Ciência e a Tecnologia, Portugal
2011 FEBS Youth Travel Grant (“Molecular Mechanisms in Signal Transduction and Cancer”)
European Association For Cancer Research, Reino Unido
2011 Bolsa Liga Portuguesa Contra o Cancro (5.000 EUR)
Liga Portuguesa Contra o Cancro, Portugal
2010 Bolsa Liga Portuguesa Contra o Cancro (5.000 EUR)
Liga Portuguesa Contra o Cancro, Portugal
2006 Research Fellowship from the Luso-American Development Foundation (FLAD)
Fundação Luso-Americana, Portugal
2003 Erasmus fellowship